This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.
Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
by Zacks Equity Research
Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.
Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.
Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?
by Zacks Equity Research
Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.
NanoString Technologies, Inc. (NSTG) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NanoString Technologies, Inc. (NSTG).
What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
by Zacks Equity Research
Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.
4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
by Zacks Equity Research
Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.
NanoString Technologies (NSTG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of 6.67% and 10.49%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NanoString Technologies (NSTG) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
NanoString (NSTG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in NanoString Technologies (NSTG) Stock?
by Zacks Equity Research
Investors need to pay close attention to NanoString Technologies (NSTG) stock based on the movements in the options market lately.
NanoString Technologies (NSTG) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -12.68% and -0.42%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Top Performing Stocks of the Best ETF of May
by Sweta Killa
Inside the best performing stocks of the top ETF of May - ARKG.
What Makes Nanostring Technologies (NSTG) a Strong Sell?
by Zacks Equity Research
Investors may consider dropping NanoString Technologies, Inc. (NSTG), that has not only witnessed a significant price decline in the past four weeks, but also has seen negative earnings estimate revisions.
Align Poised On Global Expansion & Invisalign Teen Growth
by Zacks Equity Research
On Jan 10, 2017, we issued an updated research report on California-based Align Technology Inc. (ALGN).
Illumina (ILMN) Launches NovaSeq Series for $100 Genome
by Zacks Equity Research
Illumina, Inc. (ILMN) recently unveiled the NovaSeq Series, a scalable sequencing solution expected to enable a $100 genome.
QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.
LLabCorp: Reimbursement Scenario a Drag Amid Other Woes
by Zacks Equity Research
On Jan 09, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH) or LabCorp.
ResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders
by Zacks Equity Research
ResMed Inc. (RMD) recently formed a joint venture with renowned surgeon and television host Dr. Mehmet Oz and private equity firm Pegasus Capital Advisors, L.P.
Myriad Genetics: Evidence Street Reviews EndoPredict Test
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN) recently announced that Blue Cross Blue Shield Association's technical assessment provider Evidence Street has reviewed its EndoPredict assay.